Tuesday 13 October 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.01
0.44
−5.91%
Follow ARVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 1.59% | (42.28%) | (16.23%) | (10.17%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 3 | 4 | 4 | |
| 1.17% | (26.85%) | (8.93%) | (5.82%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1.62% | (42.53%) | (14.34%) | (8.52%) | |
Average Days of Receivables |
62.58 | 26.13 | 8.90 | 31.32 | |
Free Cash Flow per Share |
(3.22) | (4.01) | (3.89) | (4.50) | |
Free Cash Flow |
(208.80) | (256.90) | (275.70) | (329.50) | |
Capital Expenditures |
(1.80) | (2.80) | (1.90) | (2.00) | |
| Other line items | |||||
Cash ROIC |
(18.47%) | (25.64%) | (24.62%) | (24.36%) | |
Accounts Receivable Turnover |
9.69 | 12.08 | 26.13 | 15.01 | |
Accounts Payable Turnover |
0.27 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
1,360.93 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
(0.07) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
75.37% | 284.90% | 108.61% | 98.43% | |
Selling, General and Administrative Expense of Revenue |
27.50% | 98.88% | 36.52% | 34.23% | |
Share Based Compensation of Revenue |
11.59% | 45.97% | 16.76% | 18.83% | |
Operating CF/Net income |
(22.26) | 1.15 | 3.39 | 5.60 | |
Depreciation/Fixed assets |
0.04 | (0.80) | (0.63) | (0.81) | |
Capex/Depreciation |
(9.00) | 0.64 | 0.58 | 0.45 | |
Revenue per Share |
4.89 | 1.40 | 3.70 | 4.27 | |
Operating CF per Share |
(3.19) | (3.97) | (3.86) | (4.47) | |
Capex per Share |
(0.03) | (0.04) | (0.03) | (0.03) | |
Capex to Sales |
0.01 | 0.03 | 0.01 | 0.01 |
Columns are period end dates